1 |
GABRILOVICH D I, NAGARAJ S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol, 2009, 9(3): 162-174.
|
2 |
SERAFINI P. Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly[J]. Immunol Res, 2013, 57(1/2/3): 172-184.
|
3 |
MASTIO J, CONDAMINE T, DOMINGUEZ G, et al. Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs[J]. J Exp Med, 2019, 216(9): 2150-2169.
|
4 |
OSTRAND-ROSENBERG S, SINHA P, FIGLEY C, et al. Frontline science: myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice[J]. J Leukoc Biol, 2017, 101(5): 1091-1101.
|
5 |
GREENE S, ROBBINS Y, MYDLARZ W K, et al. Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models[J]. Clin Cancer Res, 2020, 26(6): 1420-1431.
|
6 |
ZHAO L N, BJÖRKLUND M, CALDEZ M J, et al. Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential[J]. Oncogene, 2021, 40: 2339-2354.
|
7 |
CHOU A, LEE S H, ZHU F Y, et al. An orthogonal metabolic framework for one-carbon utilization[J]. Nat Metab, 2021, 3(10): 1385-1399.
|
8 |
ZHU Z Y, LEUNG G K K. More than a metabolic enzyme: mthfd2 as a novel target for anticancer therapy?[J]. Front Oncol, 2020, 10: 658.
|
9 |
KESARI S, WAGLE N, CARRILLO J A, et al. Pilot study of high-dose pemetrexed in patients with progressive chordoma[J]. Clin Cancer Res, 2024, 30(2): 323-333.
|
10 |
HUANG J J, ZHAO Y, ZHAO K X, et al. Function of reactive oxygen species in myeloid-derived suppressor cells[J]. Front Immunol, 2023, 14: 1226443.
|
11 |
VEGLIA F, TYURIN V A, BLASI M, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer[J]. Nature, 2019, 569(7754): 73-78.
|
12 |
LIMAGNE E, NUTTIN L, THIBAUDIN M, et al. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells[J]. Cancer Cell, 2022, 40(2): 136-152.e12.
|
13 |
SCHAER D A, GEEGANAGE S, AMALADAS N, et al. The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy[J]. Clin Cancer Res, 2019, 25(23): 7175-7188.
|
14 |
NAGARAJ S, GUPTA K, PISAREV V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer[J]. Nat Med, 2007, 13: 828-835.
|
15 |
FRATERNALE A, GREEN K A, SCHIAVANO G F, et al. Inhibition of myeloid-derived suppressor cell (MDSC) activity by redox-modulating agents restores T and B cell proliferative responses in murine AIDS[J]. Int Immunopharmacol, 2023, 124(Pt A): 110882.
|
16 |
SHANG M, YANG H J, YANG R, et al. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation[J]. Nat Commun, 2021, 12(1): 1940.
|
17 |
KAWAI J Y, TOKI T, OTA M, et al. Discovery of a potent, selective, and orally available MTHFD2 inhibitor (DS18561882) with in vivo antitumor activity[J]. J Med Chem, 2019, 62(22): 10204-10220.
|
18 |
JU H Q, LU Y X, CHEN D L, et al. Modulation of redox homeostasis by inhibition of MTHFD2 in colorectal cancer: mechanisms and therapeutic implications[J]. J Natl Cancer Inst, 2019, 111(6): 584-596.
|
19 |
LONG H X, JIA Q Z, WANG L Y, et al. Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy[J]. Cancer Cell, 2022, 40(6): 674-693.e7.
|
20 |
CHEN J, SUN H W, YANG Y Y, et al. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer[J]. Signal Transduct Target Ther, 2021, 6(1): 4.
|